---
title: "Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279892027.md"
description: "Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns"
datetime: "2026-03-20T06:01:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279892027.md)
  - [en](https://longbridge.com/en/news/279892027.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279892027.md)
---

# Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns

Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns

### Related Stocks

- [PPBT.US](https://longbridge.com/en/quote/PPBT.US.md)

## Related News & Research

- [Purple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum](https://longbridge.com/en/news/286559312.md)
- [Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights | PPBT Stock News](https://longbridge.com/en/news/286556016.md)
- [U.S. ENLISTS SMALL BIOTECH FIRM FOR EXPERIMENTAL EBOLA TREATMENT](https://longbridge.com/en/news/287107550.md)
- [Global Stocks, American Dollars: How ADRhedged™ ETFs Are Fixing the Most Overlooked Risk in International Investing](https://longbridge.com/en/news/286777327.md)
- [A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data](https://longbridge.com/en/news/286722721.md)